VestGen Advisors LLC grew its stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 296.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,250 shares of the financial services provider’s stock after acquiring an additional 14,400 shares during the quarter. VestGen Advisors LLC’s holdings in iShares Biotechnology ETF were worth $4,053,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. William Mack & Associates Inc. purchased a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth about $89,000. Willow Creek Wealth Management Inc. acquired a new stake in shares of iShares Biotechnology ETF in the third quarter worth approximately $204,000. MADDEN SECURITIES Corp purchased a new stake in iShares Biotechnology ETF during the third quarter valued at about $100,000. Latitude Advisors LLC acquired a new position in iShares Biotechnology ETF during the third quarter valued at approximately $84,000. Finally, Ashton Thomas Securities LLC purchased a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at $550,000. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Stock Up 0.7%
NASDAQ IBB opened at $217.86 on Friday. iShares Biotechnology ETF has a 1 year low of $154.62 and a 1 year high of $220.31. The business’s fifty day moving average is $208.29 and its two-hundred day moving average is $184.58.
iShares Biotechnology ETF Cuts Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.0112 per share. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. The ex-dividend date was Tuesday, September 15th. This represents a $0.04 annualized dividend and a yield of 0.0%.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
